Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
Open accessAbstract
PD‐1/PD‐L1 (programmed cell death‐1 and programmed death‐ligand 1) inhibitors utilization in neoadjuvant therapy has been assessed in tumors. This study focused on the clinical benefits of neoadjuvant anti‐PD‐1/PD‐L1 therapy. A comprehensive search was conducted in electronic databases to identify eligible studies. Major response rate (MRR) and complete response rate (CRR) were pooled in this analysis to assess the efficacy of neoadjuvant anti‐PD‐1/PD‐L1 utilization, all grades and high‐grade adverse events (AEs) were pooled to evaluate its safety. Twenty studies were included in this meta‐analysis, with 828 patients suffering from different tumors. The pooled CRR of triple‐negative breast cancer was 0.569 (95% CI 0.514, 0.624, I2 = 0%) and the pooled MRR of lung cancer was 0.471 (95% CI 0.267, 0.575, I2 = 0%). The most frequent adverse event was fatigue (0.272 95% CI 0.171, 0.402, I2 = 87%), and the most common high‐grade adverse event was febrile neutropenia (0.084 95% CI 0.063, 0.112, I2 = 85%). In conclusion, neoadjuvant anti‐PD‐1/PD‐L1 therapy received satisfactory clinical results in these tumors included.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PD-L1 induces immune evasion by targeting PD-1 on activated T cells, resulting in T cell exhaustion.
“induces immune evasion by targeting its ligand, programmed cell death 1 (PD-1) on activated T cells, resulting in T cell exhaustion1–4.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [4]
The Introduction (page not provided) says PD-L1 binds PD-1 on T cells, suppresses their activity, and enhances tumor immune escape. The Discussion (page not provided) identifies activated T cells as expressing PD-1. Neither passage says this interaction results in T-cell exhaustion, so that part of the claim is not supported by our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measuredPD-L1 is widely expressed in various malignancies.
“Programmed death ligand 1 (PD-L1, namely CD274) is widely expressed in various malignancies”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 56 · Cited by 23
Research works printed but not linked: 1
- [45]Review Manager (RevMan) [computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
- Authors
- Li, Z., Wu, X., Zhao, Y., Xiao, Y., Zhao, Y., Zhang, T., Li, H., Sha, F., Wang, Y., Deng, L., & Ma, X.
- Affiliations
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- State University of New York (US)
- Weiss Memorial Hospital (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Ma, Xuelei
- ORCID
- Venue
- MedComm
- Publisher
- Wiley
- Published
- 2021-03
- Volume
- 2
- Issue
- 1
- Pages
- 60-68
- ISSN
- 2688-2663 (ISSN-L)
- PMC
- PMC8491227
- OpenAlex
- W3138565626
- Cited by
- 23
- References
- 56
- Citations by year
- 2025: 2 · 2024: 7 · 2023: 5 · 2022: 9
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- MedComm (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- neoadjuvant therapy, PD-1/PD-L1 blockade, immune checkpoint inhibitors, triple-negative breast cancer, lung cancer, complete response rate, adverse events, fatigue, febrile neutropenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
